mediated coupling of the resulting free acid with 7-hydroxy-4-
methylcoumarin to give the (non-fluorescent) ester A4. Treatment
of A4 with CH3OH/NEt3, as described above, led to the rapid
release of 7-hydroxy-4-methylcoumarin (as a fluorescent compo-
nent) with the concomitant formation of c-lactam C1.
In conclusion, we have shown that incorporation of a vinyl ester
exocyclic to the b-lactam ring of a penicillin nucleus enables this to
act as a b-lactamase-dependent prodrug – rapid release of the
(unactivated) alkoxy component of the vinyl ester is triggered by
enzyme-catalysed hydrolysis of the b-lactam ring. The vinyl ester
sidechain is more amenable to synthetic variation than the
S-aminosulfenimine unit, with the result that the scope to configure
penams as b-lactamase-dependent prodrugs is extended consider-
ably. Potential applications of such materials arise in combating
certain forms of antibiotic resistance (via release of an antimicrobial
entity – e.g. triclosan8 – on contact with a b-lactamase enzyme), in
the ADEPT mode of drug targeting9 (e.g. via site-specific release
and activation of DNA-minor-groove alkylating agents related to
Carzelesin10), and in the development of chromogenic and
fluorogenic substrates11 as diagnostics for certain classes of
b-lactamase enzymes.
We are grateful to N. Hurley, T. Greene, J. Grant and L. Kirby
for technical assistance, to Dr D. McCarthy (UCC) for high-
resolution NMR spectra, to Ken Harris (Scripps Center for Mass
Spectrometry) and Dr D. O’Shea (UCD) for high-resolution mass
spectra, and to IRCSET for financial support (C. C. R).
Notes and references
Scheme 3
1 (a) T. P. Smyth, M. E. O’Donnell, M. J. O’Connor and J. O. St Ledger,
Tetrahedron, 2000, 56, 5699–5707; (b) T. P. Smyth, M. E. O’Donnell,
M. J. O’Connor and J. O. St Ledger, J. Org. Chem., 1998, 63, 7600–7618;
(c) T. P. Smyth, M. J. O’Connor and M. E. O’Donnell, J. Org. Chem.,
1999, 64, 3132–3138.
2 (a) J. D. Buynak, A. S. Rao and S. D. Nidamarthy, Tetrahedron Lett.,
1998, 39, 4945–4946; (b) J. D. Buynak, Patent number WO 99/33837,
1999; (c) J. D. Buynak, K. Wu, B. Bachmann, D. Khasnis, L. Hua,
H. K. Nguyen and C. L. Carver, J. Med. Chem., 1995, 38, 1022–1034;
(d) J. D. Buynak, V. R. Doppalapudi and G. Adam, Bioorg. Med. Chem.
Lett., 2000, 10, 853–857.
liberation of methanol and formation of the co-product were
complete in less than 20 min. The co-product that was generated in
the buffer- and enzyme-catalysed processes was identical; the H,
1
13C NMR and HRMS data{ of this material support its
identification as the c-lactam C’. Thus, the kinetically dominant
nucleophile toward
a carbonyl group is the thiazolidine-
ring nitrogen whilst this role falls to the thiazolidine-ring sulfur
in the the S-aminosulfenimine which has a sulfur atom as the
electron-deficient centre.
The role of the unsaturated linker in facilitating the intramo-
lecular displacement within the ring-cleaved structure was assessed
by studying carbamate E. This was completely converted to the
ring-opened structure F after 45 min in methanol containing
y0.2 M NEt3; no ring-fused imidazolidinone structure7 was
formed. It is clear that the unsaturated linker is essential for
rapid release of the simple alkoxy component of the ester in the
b-lactam-ring-cleaved structures such as B3’.
3 Structure C1 was shown by semiempirical modelling (AM1) to be
approximately 14 kcal mol21 more stable than its isomeric form C.
4 In the case of B1, steric hindrance by the t-butyl group blocks addition of
the nucleophile to the ester carbonyl, which is the rate-determining step.
5 A parallel for this is found in the intramolecular nucleophilic addition
that occurs within the b-lactam-ring-cleaved structure derived from 6(Z)-
acetylmethylenepenicillanic acid (a potent b-lactamase inhibitor):
M. Arisawa and S. Adam, Biochem. J., 1983, 211, 447–454.
6 6(Z)-t-butoxycarbonylmethylenepenicillanate and 6(Z)-methoxycarbo-
nylmethylenepenicillanate have been found to be b-lactamase substrates
(the corresponding sulfones are inhibitors), however, the fate of the
b-lactam-ring-cleaved structures was not reported on: (a) J. D. Buynak,
B. Geng, B. Bachmann and L. Hua, Bioorg. Med. Chem. Lett., 1995, 5,
1513–1518; (b) D. Habich and K. Metzger, Heterocycles, 1986, 24, 289–
296.
7 J. Marchand-Brynaert, H. Vanlierde and L. Ghosez, Bull. Soc. Chim.
Belg., 1988, 97, 1081–1093.
8 Q. Li, J. Y. Lee, R. Castillo, M. S. Hixon, C. Pujol, V. R. Doppalapudi,
H. M. Shepard, G. M. Wahl, T. J. Lobl and M. F. Chan, Antimicrob.
Agents Chemother., 2002, 46, 1262–1268.
9 (a) H. P. Svensson, I. S. Frank, K. K. Berry and P. D. Senter, J. Med.
Chem., 1998, 41, 1507–1512 and references therein; (b) T. W. Hudyma,
K. Bush, K. L. Colson, R. A. Firestone and H. D. King, Bioorg. Med.
Chem. Lett., 1993, 3, 323–328.
10 A. Awada, C. J. A. Punt, M. J. Piccart, O. van Tellingen, L. van Manen,
J. Kerger, Y. Groot, J. Wanders, J. Verweij and D. J. Wagener, Br.
J. Cancer, 1999, 79, 1454–1461 and references therein.
Variation of the displaceable moiety was achieved by selective
removal (Pd(PPh3)4) of the allyl group of A2 followed by DCC
11 W. Gao, B. Xing, R. Y. Tsien and J. Rao, J. Am. Chem. Soc., 2003, 125,
11146–11147 and references therein.
C h e m . C o m m u n . , 2 0 0 4 , 2 3 3 2 – 2 3 3 3
2 3 3 3